BACKGROUND
Only 3%-5% of patients with cancer nationwide enroll in clinical trials. Although participation among patients with solid tumors has been well studied, data in the hematopoietic stem cell transplantation (HSCT) setting remain limited. We sought to (1) describe clinical trial participation rates by HSCT type;...
Tamryn Fowler, R. Brazauskas, Jinalben Patel et al.· The Journal of the National...· 0 citations
It is suggested that PTCy narrows outcome differences across donor types, shifting donor selection from rigid hierarchies and supporting timely HCT using the best available donor.
Y. Aljawai, Masumi Ueda Oshima, Varuna Astha et al.· Blood Advances· 0 citations
Among adult ACCESS recipients treated on a uniform young-donor PBSC/PTCy platform, short-term outcomes with predominantly 6/8 MMUD transplantation were encouraging and should not be interpreted as establishing equivalence with 7/8 MMUD transplantation.
A. J. Jimenez Jimenez, Joseph Stanek, Brent Logan et al.· Blood Advances· 0 citations
MMUD with PTCy-based GVHD prophylaxis and RIC/NMA conditioning was safe and effective to facilitate HCT and outcomes were similar in the expansion cohort that enrolled from a greater number of centers.
Brian C. Shaffer, M. A. Al Malki, Antonio M. Jimenez et al.· American journal of hematolo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.